DK1272897T3 - Adenosin-A2A-receptorantagonister til behandling og forebyggelse af leverfibrose, cirrose og fedtlever - Google Patents

Adenosin-A2A-receptorantagonister til behandling og forebyggelse af leverfibrose, cirrose og fedtlever

Info

Publication number
DK1272897T3
DK1272897T3 DK01910529T DK01910529T DK1272897T3 DK 1272897 T3 DK1272897 T3 DK 1272897T3 DK 01910529 T DK01910529 T DK 01910529T DK 01910529 T DK01910529 T DK 01910529T DK 1272897 T3 DK1272897 T3 DK 1272897T3
Authority
DK
Denmark
Prior art keywords
adenosine
cirrhosis
liver
prevention
treatment
Prior art date
Application number
DK01910529T
Other languages
Danish (da)
English (en)
Inventor
Bruce N Cronstein
Edwin Chan
Original Assignee
Univ New York
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ New York filed Critical Univ New York
Application granted granted Critical
Publication of DK1272897T3 publication Critical patent/DK1272897T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Toxicology (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
DK01910529T 2000-02-10 2001-02-12 Adenosin-A2A-receptorantagonister til behandling og forebyggelse af leverfibrose, cirrose og fedtlever DK1272897T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US18154600P 2000-02-10 2000-02-10
PCT/US2001/004341 WO2001058241A2 (fr) 2000-02-10 2001-02-12 Antagonistes des recepteurs d'adenosine a2a pour le traitement et la prevention de la cirrhose hepatique et de la steatose hepatique

Publications (1)

Publication Number Publication Date
DK1272897T3 true DK1272897T3 (da) 2008-09-15

Family

ID=22664744

Family Applications (1)

Application Number Title Priority Date Filing Date
DK01910529T DK1272897T3 (da) 2000-02-10 2001-02-12 Adenosin-A2A-receptorantagonister til behandling og forebyggelse af leverfibrose, cirrose og fedtlever

Country Status (11)

Country Link
US (1) US6555545B2 (fr)
EP (1) EP1272897B1 (fr)
JP (1) JP2004502640A (fr)
AT (1) ATE394104T1 (fr)
AU (2) AU2001238124B2 (fr)
CA (1) CA2398908C (fr)
DE (1) DE60133887D1 (fr)
DK (1) DK1272897T3 (fr)
ES (1) ES2307593T3 (fr)
PT (1) PT1272897E (fr)
WO (1) WO2001058241A2 (fr)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6196459B1 (en) * 1998-05-11 2001-03-06 Ubiq Incorporated Smart card personalization in a multistation environment
WO2003080649A2 (fr) * 2002-03-20 2003-10-02 Regents Of The University Of Minnesota Induction de la proliferation d'hepatocytes in vitro par inhibition d'inhibiteurs du cycle cellulaire
ITRM20070088A1 (it) * 2007-02-19 2008-08-20 Francesco Fringuelli Composti derivati della colchicina, procedimento per la loro preparazione e usi in campo medico.
US20120121540A1 (en) * 2007-08-10 2012-05-17 Franz Ulrich Schmitz Certain Nitrogen Containing Bicyclic Chemical Entities For Treating Viral Infections
WO2009055021A1 (fr) * 2007-10-26 2009-04-30 New York University School Of Medicine Procédés et compositions pour le traitement de maladies hépatiques
ES2541141T3 (es) * 2008-01-31 2015-07-16 Astellas Pharma Inc. Composición farmacéutica para el tratamiento de las enfermedades del hígado graso
US8536306B2 (en) 2008-10-01 2013-09-17 The Scripps Research Institute Human A2A adenosine receptor crystals and uses thereof
US20100204265A1 (en) * 2009-02-09 2010-08-12 Genelabs Technologies, Inc. Certain Nitrogen Containing Bicyclic Chemical Entities for Treating Viral Infections
JP5765239B2 (ja) 2009-03-13 2015-08-19 アドヴィナス・セラピューティックス・リミテッド 置換縮合ピリミジン化合物
HUE025704T2 (en) * 2009-03-20 2016-04-28 Sigma Tau Ind Farmaceuti Oxidized triazolyl purine derivatives used as adenosine A2A receptor ligands and their use as medicaments
US8796290B2 (en) 2009-11-09 2014-08-05 Advinus Therapeutics Limited Substituted fused pyrimidine compounds, its preparation and uses thereof
DK2531492T3 (en) 2010-02-05 2016-07-04 Heptares Therapeutics Ltd 1,2,4-triazin-4-amine derivatives
WO2012066330A1 (fr) 2010-11-17 2012-05-24 Heptares Therapeutics Limited Composés utiles en tant qu'inhibiteurs du récepteur a2a
US20200369665A1 (en) 2017-06-30 2020-11-26 Ryvu Therapeutics S.A. Imidazo[1,2-a]pyrazine modulators of the adenosine a2a receptor
WO2019123482A1 (fr) 2017-12-19 2019-06-27 Impetis Biosciences Ltd. Composition pharmaceutique pour le traitement du cancer
IL275817B2 (en) 2018-01-04 2024-04-01 Impetis Biosciences Ltd Tricyclic compounds, compositions and medicinal applications thereof
WO2020128036A1 (fr) 2018-12-21 2020-06-25 Ryvu Therapeutics S.A. Modulateurs du récepteur a2a de l'adénosine
IL325890A (en) 2023-07-17 2026-03-01 Ryvu Therapeutics S A Adenosine A2A and A2B receptor modulator

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4705658A (en) 1986-04-07 1987-11-10 Capsule Technology International, Ltd. Method for drying gelatin in the manufacture of hard shell gelatin capsules
US5063233A (en) 1986-11-14 1991-11-05 Ciba-Geigy Corporation N9 -cyclopentyl-substituted adenine derivatives useful as adenosine receptor agonists
US4968697A (en) 1987-02-04 1990-11-06 Ciba-Geigy Corporation 2-substituted adenosine 5'-carboxamides as antihypertensive agents
US5036381A (en) 1990-06-15 1991-07-30 Motorola, Inc. Multiple electronic devices within a single carrier structure
GB2264948B (en) 1992-03-13 1996-10-16 Merck & Co Inc Human adenosine receptors
US5426101A (en) 1992-09-30 1995-06-20 Merrell Dow Pharmaceuticals Inc. 2-substituted adenosines with A-2 receptor affinity
AU6516494A (en) 1993-04-15 1994-11-08 New York University Adenosine receptor agonists for the promotion of wound healing
US5877180A (en) * 1994-07-11 1999-03-02 University Of Virginia Patent Foundation Method for treating inflammatory diseases with A2a adenosine receptor agonists
US5859019A (en) 1997-03-07 1999-01-12 Trustees Of The University Of Pennsylvania Methods for protecting against cardiac ischemia by administering adenosine A2a receptor antagonists
AU750322B2 (en) 1997-05-09 2002-07-18 Trustees Of The University Of Pennsylvania, The Methods and compositions for reducing ischemic injury of the heart by administering adenosine receptor agonists and antagonists
WO1998052611A1 (fr) * 1997-05-23 1998-11-26 Nippon Shinyaku Co., Ltd. Preparation medicamenteuse aux fins de la prevention et du traitement des hepatopathies
US5916910A (en) 1997-06-04 1999-06-29 Medinox, Inc. Conjugates of dithiocarbamates with pharmacologically active agents and uses therefore
US6303619B1 (en) * 1998-03-12 2001-10-16 University Of Virginia Meta-substituted acidic 8-phenylxanthine antagonists of A3 human adenosine receptors
US6232297B1 (en) * 1999-02-01 2001-05-15 University Of Virginia Patent Foundation Methods and compositions for treating inflammatory response

Also Published As

Publication number Publication date
WO2001058241A9 (fr) 2002-10-17
DE60133887D1 (de) 2008-06-19
AU3812401A (en) 2001-08-20
ES2307593T3 (es) 2008-12-01
ATE394104T1 (de) 2008-05-15
PT1272897E (pt) 2008-08-18
CA2398908C (fr) 2009-12-15
WO2001058241A2 (fr) 2001-08-16
JP2004502640A (ja) 2004-01-29
EP1272897A2 (fr) 2003-01-08
AU2001238124B2 (en) 2006-05-25
US20020002145A1 (en) 2002-01-03
US6555545B2 (en) 2003-04-29
EP1272897B1 (fr) 2008-05-07
CA2398908A1 (fr) 2001-08-16

Similar Documents

Publication Publication Date Title
DE60133887D1 (de) Adenosin a2a rezeptor-antagonisten zur behandlung und vorbeugung von leberfibrose, zirrhose und fettleber
WO2005027895A3 (fr) Analogues d'hormone thyroidienne et methodes d'utilisation associees
DK1135153T3 (da) Anvendelser af EPH-receptorantagonister og -agonister til behandling af vaskulære forstyrrelser
SG155054A1 (en) Human anti- neutralizing antibodies as selective pathway inhibitors
MXPA02012443A (es) Profarmaco en 3'' de 2'-desoxi-beta-l-nucleosidos.
CY1119536T1 (el) Συνθεση μονομερων προστατευμενου 3'-αμινο νουκλεοζιδιου
DK1173441T3 (da) 6-alkenyl-, 6-alkynyl- og 6-epoxy-epothilon-derivater, fremgangsmåde til fremstilling af disse samt deres anvendelse i farmaceutiske sammensætninger
DK1523489T3 (da) Modificerede 2'- og 3'-nukleosidprodrugs til behandling af flaviridae-infektioner
DK1268616T3 (da) Fyldstofkoncentrater til anvendelse i termoplaster
WO2006031922A3 (fr) Analogues d'hormones thyroidiennes et procedes d'utilisation correspondants
ATE364595T1 (de) Pyridoxin- und pyridoxalanaloga als cardiovasculäre therapeutika
ATE506959T1 (de) Verwendung von il-18 inhibitoren
MX2007003078A (es) Compuestos de imidazoquinolina.
WO2008043107A3 (fr) Utilisation d'antagonistes des jonctions occlusives pour traiter les affections abdominales inflammatoires
JP2004502640A5 (fr)
PT1513836E (pt) Derivados de piperazinilacilpiperidina, sua preparacao e sua aplicacao em terapeutica
EP1334221A4 (fr) Protection cathodique en acier dans du beton arme par traitement electro-osmotique
AP2001002285A0 (en) Immunomodulatory steroids, in particular the hemihydrate of. 16 alpha.-bromoepiandrosterone.
TW200624125A (en) Compositions and methods for increasing HDL and HDL-2b levels
DK1411970T3 (da) Anvendelse af SARP-1 til behandling og/eller forebyggelse af sclerodermia
DK1058544T3 (da) Inhibition af TNF-aktivitet med præparater, der omfatter heparin og oplöselige TNF-receptorer
AR026901A1 (es) Peptidos con n-alquilacion que tienen actividad antiangiogenica
NO20051261L (no) Morfin-6-glukuronidsalt
IT1307736B1 (it) Ossopiperazinil derivati e composizioni fotostabilizzate.
BR0002640A (pt) Uso de simeticona para tratar colite ulcerativa